Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,…

By R. Stupp, M. Hegi, T. Gorlia, S. Erridge, J. Perry, Yong-Kil Hong, Kenneth D. Aldape, B. Lhermitte, T. Pietsch, D. Grujicic and 27 more. The Lancet Oncology, 2014

903 citations recorded by the source corpus.

Subfields: Genetics, Immunology and Allergy, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e15c3a8fca96cd4f2d529fd0912816548ef9deec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael Weller
2. F. Giancotti

In Immunology and Allergy

1. Jonathan M Cooper
2. F. Giancotti

In Molecular Biology

1. Jonathan M Cooper
2. P. Wen
3. F. Giancotti

Citations in the corpus

• Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance (2019, result): “Despite encouraging results from initial phase I and II trials, the phase II CORE and phase III CENTRIC trials failed to meet overall survival endpoints (Stupp et al., 2014).”
• Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015, background): “For example, 3 large phase 3 trials were completed, based on promising phase 3 data, which failed to significantly extend OS.5,6,16 These failures highlight the need to optimize the use of imaging as a surrogate tool to better understand the response to novel therapeutics.”